Wie hoch ist die Marktkapitalisierung für Shanghai Haohai Biological Technology Co., Ltd. (688366)

Marktkapitalisierung für Shanghai Haohai Biological Technology Co., Ltd. (688366) ist $835.72M

Shanghai Haohai Biological Technology Co., Ltd. (688366) Operative Marge

Q: Wie hoch ist der Preis für Shanghai Haohai Biological Technology Co., Ltd. (688366)

Preis für Shanghai Haohai Biological Technology Co., Ltd. (688366) ist $4.39

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and distribution of advanced biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various international markets. The company's extensive product portfolio serves multiple medical fields. For ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, specialized orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. In orthopedics, they provide sodium hyaluronate injections and medical chitosan. Their wound care segment features recombinant human epidermal growth factor, effective in treating a broad spectrum of injuries, including burns, residual wounds, donor site trauma, post-traumatic wounds, and both acute and chronic ulcerations. Anti-adhesion solutions are offered in the form of medical sodium hyaluronate gel and medical chitosan, while hemostatic products include collagen sponges and porcine fibrin sealants. Within medical aesthetics, Shanghai Haohai produces a diverse range of hyaluronic acid (HA) dermal fillers: Matrifill, a first-generation mono-phase injectable gel; Janlane, a second-generation filler engineered for dynamic applications; and Hyalumatrix, a third-generation product designed for precise aesthetic enhancements. This division also supplies radio frequency devices and laser equipment. Beyond its core product offerings, the company actively pursues research and development in biological engineering and pharmaceutical innovations. It also provides related technology transfer and consultation services, alongside engaging in investment and trading activities. Originally established in 2007 as Haohai Limited, the company adopted its current name, Shanghai Haohai Biological Technology Co., Ltd., in 2010 and is headquartered in Shanghai, China.

Jahr	Operative Marge	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Operative Marge

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Operative Marge	Differenz der operativen Marge	Land
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Moderna, Inc. MRNA.US	-149.01%	-	US
Lonza Group AG LONN.SW	0.00%	-	CH

Unternehmen

Operative Marge

Differenz der operativen Marge

Land